| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID273111 | Effect on ventral prostate weight in po dosed CD1 mouse after 7 days | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID300595 | Binding affinity to human ERbeta | 2007 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
| Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 3: synthesis of cyclopentanone and cyclohexanone intermediates for C-ring modification. |
| AID273113 | Effect on dihydro testosterone level in CD1 mouse plasma at 0.1 mg/kg, po after 7 days | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID273106 | Activity at ERalpha in PC3 cells by transcription assay | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID273116 | Effect on seminal vesicle weight in po dosed CD1 mouse after 7 days | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID300597 | Selectivity for human ERbeta over human ERalpha | 2007 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
| Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 3: synthesis of cyclopentanone and cyclohexanone intermediates for C-ring modification. |
| AID300826 | Displacement of [3H]estradiol from human recombinant ERbeta | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
| Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 4: functionalization of the benzopyran A-ring. |
| AID273109 | Activity at ERbeta in PC3 cells relative to diethylstibesterol by transcription assay | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID300827 | Ratio of Ki for ERalpha to Ki for ERbeta | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
| Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 4: functionalization of the benzopyran A-ring. |
| AID273110 | Selectivity for ERbeta over ERalpha in PC3 cells relative to diethylstibesterol by transcription assay | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID273114 | Ventral prostate involution in CD1 mouse at 30 mg/kg, po after 7 days | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID273103 | Displacement of [3H]estradiol from human recombinant ERalpha | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID273107 | Activity at ERalpha in PC3 cells relative to diethylstibesterol by transcription assay | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID273108 | Activity at ERbeta in PC3 cells by transcription assay | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID273115 | Effect on testes weight in po dosed CD1 mouse after 7 days | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID273105 | Selectivity for ERbeta over ERalpha | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID273104 | Displacement of [3H]estradiol from human recombinant ERbeta | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID300596 | Binding affinity to human ERalpha | 2007 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
| Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 3: synthesis of cyclopentanone and cyclohexanone intermediates for C-ring modification. |
| AID273112 | Effect on testosterone level in CD1 mouse plasma at 0.1 mg/kg, po after 7 days | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID301350 | Binding affinity at ERalpha | 2007 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
| Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 5: Combined A- and C-ring structure-activity relationship studies. |
| AID300825 | Displacement of [3H]estradiol from human recombinant ERalpha | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
| Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 4: functionalization of the benzopyran A-ring. |
| AID301349 | Binding affinity at ERbeta | 2007 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
| Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 5: Combined A- and C-ring structure-activity relationship studies. |
| AID301351 | Selectivity ratio of Ki for ERbeta over Ki for ERalpha | 2007 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
| Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 5: Combined A- and C-ring structure-activity relationship studies. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID977610 | Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID1811 | Experimentally measured binding affinity data derived from PDB | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID1797927 | Estrogen Receptor Binding Assay and Cell-Based Transcriptional Assay from Article 10.1021/jm060491j: \\Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia.\\ | 2006 | Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
| Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
| AID1797931 | Estrogen Receptor Binding Assay. from Article 10.1016/j.bmcl.2007.08.009: \\Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 5: Combined A- and C-ring structure-activity relationship studies.\\ | 2007 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
| Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 5: Combined A- and C-ring structure-activity relationship studies. |
| AID1797929 | Estrogen Receptor Binding Assay. from Article 10.1016/j.bmcl.2007.06.052: \\Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 3: synthesis of cyclopentanone and cyclohexanone intermediates for C-ring modification.\\ | 2007 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
| Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 3: synthesis of cyclopentanone and cyclohexanone intermediates for C-ring modification. |
| AID1797928 | Estrogen Receptor Binding Assay. from Article 10.1016/j.bmcl.2007.04.051: \\Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 2: structure-activity relationship studies on the benzopyran scaffold.\\ | 2007 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
| Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 2: structure-activity relationship studies on the benzopyran scaffold. |
| AID1797930 | Estrogen Receptor Binding Assay. from Article 10.1016/j.bmcl.2007.07.009: \\Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 4: functionalization of the benzopyran A-ring.\\ | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
| Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 4: functionalization of the benzopyran A-ring. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |